A detailed history of Federated Hermes, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 154,192 shares of IMVT stock, worth $4.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
154,192
Holding current value
$4.24 Million
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$27.51 - $27.51 $4.24 Million - $4.24 Million
154,192 New
154,192 $4.24 Million
Q4 2023

Jan 31, 2024

SELL
$31.31 - $44.19 $11.2 Million - $15.8 Million
-356,609 Reduced 99.17%
2,979 $125,000
Q3 2023

Nov 13, 2023

BUY
$18.55 - $39.96 $5.75 Million - $12.4 Million
310,163 Added 627.54%
359,588 $13.8 Million
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $43,551 - $72,841
-3,067 Reduced 5.84%
49,425 $937,000
Q1 2023

May 08, 2023

BUY
$15.27 - $19.72 $151,539 - $195,701
9,924 Added 23.31%
52,492 $814,000
Q4 2022

Feb 13, 2023

BUY
$6.59 - $17.75 $215,545 - $580,567
32,708 Added 331.72%
42,568 $755,000
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $7.36 Million - $11.9 Million
-1,872,491 Reduced 99.48%
9,860 $55,000
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $72,815 - $121,717
-21,543 Reduced 1.13%
1,882,351 $7.34 Million
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $7.11 Million - $12.3 Million
1,404,404 Added 281.17%
1,903,894 $10.5 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $3.57 Million - $4.53 Million
486,456 Added 3732.21%
499,490 $4.26 Million
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $91,368 - $148,196
13,034 New
13,034 $113,000
Q1 2021

May 13, 2021

SELL
$13.08 - $49.6 $2.24 Million - $8.48 Million
-171,059 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$36.36 - $52.71 $5.42 Million - $7.86 Million
149,193 Added 682.31%
171,059 $7.9 Million
Q3 2020

Nov 12, 2020

BUY
$22.61 - $38.9 $494,390 - $850,587
21,866 New
21,866 $769,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.